This Project Grant award of $399,214 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by Proton Bio, Inc. to develop a novel therapy targeting the proton-sensing receptor GPR68 for the treatment of glioblastoma (GBM), the most common and aggressive form of adult brain cancer. The key objectives are to: 1) define the pharmacological properties of three lead candidate GPR68 inhibitor compounds ("ogremorphins"), 2) evaluate the...
The National Cancer Institute has awarded a $107,948 Project Grant (CFDA 93.398 Cancer Research Manpower) to Case Western Reserve University to study translation regulation and its role in glioblastoma, the most common and fatal primary brain tumor in adults. The research aims to use ribosome profiling and RNA sequencing to understand how hypoxia (low oxygen) influences translational gene regulation in glioblastoma stem-like cells. It will also investigate the integrated stress response...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) totaling $1,064,642 provides funding to Tufts Medical Center to characterize the role of the angiogenin (ANG) and plexin-B2 (PLXNB2) signaling axis in regulating the stemness properties of glioblastoma stem cells (GSCs) and preventing glioblastoma (GBM) recurrence. The key objectives are to: 1) Examine the function of the ANG/PLXNB2 axis in different GSC subtypes and distinguish the...
This $678,879 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research by the Cold Spring Harbor Laboratory (CSHL) to investigate a novel epigenetic vulnerability in glioblastoma (GBM), the most common and deadly adult primary brain cancer. The project aims to define the epigenetic mechanism by which targeting the chromatin regulator BRD8 re-establishes p53-mediated tumor suppression in GBM lacking...
This $800,000 Project Grant award by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel biologic therapy by Creative Biotherapeutics LLC to eradicate brain cancer and brain metastases. The grantee's research has identified a key extracellular protein, eGRP78, that is upregulated in drug-resistant brain tumors and drives tumor growth, immune evasion, and stem cell formation. Their lead inhibitor, CBT300, has...
The federal Project Grant award R01CA288535, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of novel cellular therapies to treat highly malignant brain tumors known as glioblastomas (GBMs). Awarded to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, the $417,858 grant will enable the research team to engineer mesenchymal stem cells (MSCs) to release bi-specific T cell engager (BiTE)...
The National Cancer Institute (NCI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $652,725 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for treating glioblastoma, a deadly brain cancer. The funded project aims to test the safety and feasibility of injecting CAR T-cells engineered to secrete a T-cell engaging antibody (CARV3.TEAM-E...
The federal Project Grant award R01CA291826, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is funding the development of GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid and sensitive molecular subtyping of gliomas. The total funding amount is $678,228, with the award starting on April 3, 2025 and a targeted completion date of March 31, 2030. The key products and services to be delivered under this...
This $717,802 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to elucidate the cellular and molecular mechanisms underlying the development of a rare and aggressive brain tumor subtype, H3.3G34-mutant high-grade glioma (HGG-G34). The research aims to unravel the transcriptional targets of the DMRTA2 gene, which is...
This Project Grant award, valued at $389,988.00 and funded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower), supports research to investigate the role of tRNA modifications in the regulation of cancer stem cell biology in glioblastoma (GBM). The University of Pittsburgh is the prime recipient of this grant, which runs from September 21, 2024 to March 31, 2027. The key objectives of this research project are to: Characterize the expression profiles of tRNA-modifying...